Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Babies born with Wolman disease can now receive a life-saving treatment on the NHS

Babies born with Wolman disease can now receive a life-saving treatment on the NHS

The new enzyme replacement therapy improves patient’s life expectancy and quality of life in clinical trials  

For the first time, an enzyme replacement therapy has been made available on the NHS for the treatment of infants born with Wolman disease, a rare and fatal genetic condition, from today (27 November).


Sebelipase alfa (Kanuma) was recommended for use on the NHS in final draft guidance by the National Institute for Health and Care Excellence (NICE), following a commercial deal secured by NHS England.

In a statement, the NHS said that the life-saving treatment will be made available to any eligible patients straight away, funded via NHSE’s Innovative Medicines Fund (IMF).

The therapy, which is manufactured by Alexion, AstraZeneca Rare Disease, will be delivered by specialist services at Manchester University NHS Foundation Trust, Birmingham Women’s and Children’s Hospital and Great Ormond Street Hospital.

NHS chief executive, Amanda Pritchard, is delighted the NHS can now offer “a life-changing treatment” to families facing this enormously difficult condition, for which previously there were no treatments.

Amanda believes that this new therapy could allow children facing this debilitating disease “to grow up, go to school and live normal lives.”

Sean Richardson, Vice President and General Manager, Alexion, UK, asserted that the recommendation is the result of continued constructive collaboration between Alexion, NICE, NHS England, patient groups, and the medical community, to ensure babies born with this life-threatening disease have a treatment available to them.”

Understand Wolman disease

A type of lysosomal acid lipase deficiency, Wolman disease is caused by mutations in a gene and is an inherited, recessive condition.

It is a rapidly-progressing condition that causes a build-up of fat in cells in the liver, heart, blood vessels, and digestive system, leading to multi-organ damage.

It occurs in around 1 in 350,000 births, with around one or two babies born every year in England estimated to have the condition.

Babies born with this condition may have symptoms such as enlarged liver and spleen, poor weight gain, low muscle tone, jaundice, vomiting, diarrhoea, developmental delay, anaemia, and malabsorption.

How Sebelipase alfa works

Clinical trials at Royal Manchester Children’s Hospital have shown this enzyme replacement therapy improves patient’s life expectancy and quality of life.

Sebelipase alfa works by replacing an enzyme missing in the body, alongside a restricted, low-fat diet.

Usually, this treatment involves weekly intravenous infusions which can be given at home, but some patients may also have a blood and marrow/stem cell transplant.

John Stewart, National Director for Specialised Commissioning, NHS England said: “It’s fantastic news that babies born with Wolman disease will be able to benefit from this life-saving treatment on the NHS from today.

“This is just the latest example of patients benefiting from innovative medicines secured through NHS commercial deals, following shortly after a new five-year medicines agreement was reached with the pharmaceutical industry that will enable rapid patient access to the treatments of tomorrow.”

For availing the new treatment, immediate funding will be provided from the IMF to enable routine patient access up to five months, but sebelipase alfa will not enter managed access.

Up to £340 million was made available through NHS England’s Innovative Medicines Fund, which launched last year, to purchase the most promising medicines and fast-track them to patients to give people the best chances of survival, or a healthier, longer life.

The Fund has already been utilised this year to provide accelerated patient access to treatments for hepatitis D and a painful long-term skin condition.

More For You

Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less
Scotland's digital patient care record

The amendment ensures that every person who receives health care or a social service in Scotland will have a digital care record

Pic credit: iStock

Scotland's move to create digital patient care record hailed

The Royal Pharmaceutical Society (RPS) in Scotland has welcomed the decision of the Scottish Parliament to create an integrated digital patient care record.

The move came during a debate on the Care Reform (Scotland) Bill on Tuesday (10), when Jackie Baillie tabled an amendment to ensure that every person who receives health care or a social service in Scotland has a digital care record.

Keep ReadingShow less
A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less